Content area

Abstract

Background

Many patients with papillary thyroid cancer (PTC) demonstrate satisfactory outcomes. However, 8%–28% of patients with PTC show tumor recurrence, which may affect prognosis. Therefore, identifying factors associated with tumor recurrence in patients with PTC may be helpful to refine therapeutic strategies.

Methods

To identify factors associated with PTC recurrence, we retrospectively reviewed demographic features (sex and age), operation method, image character, serum thyroglobulin (Tg), accumulated radioactive iodine (I-131) therapeutic dose, I-131 uptake, and metastases at diagnosis in 829 patients with PTC. Patients were grouped into early (stage I and II; n = 698) and advanced (stage III and IV; n = 131) tumor-node-metastasis (TNM) stages. Recurrence rate, mortality rate, risk factors of recurrence, recurrent free survival and overall survival curve were compared between two groups.

Results

Patients in the early stage demonstrated a lower recurrence rate (7.2%) than did those in the advanced stage (28.2%, p < 0.05). The mortality rate of patients with recurrence in the advanced stage was higher than that of those in the early stage (51.4% vs. 12.0%). The major impact factors on tumor recurrence in early TNM stage were distant metastasis and lymph node metastasis, while in advanced TNM stage were distant metastasis, male gender, total thyroidectomy with limited lymph node dissection, and a high serum Tg level.

Conclusions

Strategies to monitor tumor recurrence might be refined according to the TNM stages of PTC patients.

Details

Title
Evaluation of recurrence risk in patients with papillary thyroid cancer through tumor-node-metastasis staging: A single-center observational study in Taiwan
Author
Jui-Hung, Sun 1 ; Yan-Rong, Li 1   VIAFID ORCID Logo  ; Kuo-Hsuan Chang 2 ; Liou, Miaw-Jene 1 ; Shu-Fu, Lin 1 ; Sung-Sheng, Tsai 1 ; Ming-Chin, Yu 3 ; Hsueh, Chuen 4 ; Chen, Szu-Tah 5 

 Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan 
 Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan 
 Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan 
 Department of Pathology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan 
 Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan 
Pages
923-930
Section
Original Article
Publication year
2022
Publication date
Dec 2022
Publisher
Elsevier Limited
ISSN
23194170
e-ISSN
23202890
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3205384434
Copyright
©2021. Chang Gung University